Therapy Areas: Infectious Diseases
Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC
7 October 2026 - Swiss healthcare company Roche (SIX: RO, ROP; OTCQX: RHHBY) announced on Wednesday that it has supplied two molecular testing instruments to the Institut National de Santé Publ...
Lakewood-Amedex Biotherapeutics reports positive data for clinical candidate Nu-3 in diabetic foot ulcers
29 September 2026 - Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT), a clinical-stage biotechnology company focused on advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials f...
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
28 September 2026 - Netherlands-based holding company QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) announced on Monday that it has received US Food and Drug Administration (FDA) clearance fo...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation fo...
Lakewood-Amedex Biotherapeutics to present at H.C. Wainwright 28th Annual Global Investment Conference
9 September 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation a...
Immuron signs US distribution deal for PROIBS
4 September 2026 - Australian biopharmaceutical company Immuron Limited (ASX: IMC; NASDAQ: IMRN), which develops and commercialises targeted polyclonal antibodies for infectious diseases, announced on...